BiVACOR
HOUSTON, TX · Manufacturing · 50 employees
BiVACOR® is a clinical-stage medical device company developing the BiVACOR Total Artificial Heart, designed to be the first long-term therapy for patients with severe biventricular heart failure. The BTAH is designed to replace the native heart and address the global unmet need of patients with end-stage heart failure by providing a next-generation life-extending solution. BiVACOR was founded
Funding history
- Funding Round — $9.0M — Aug 2024
- Funding Round — $15.0M — Feb 2023
Recent signals
- Dec 18, 2024: Launched BiVACOR Implements Total Artificial Heart in Five Patients as Part of FDA Study to Evaluate Heart Transplant Feasibility.
- Aug 06, 2024: Raised $9.0M
- Jan 07, 2024: BiVACOR Appoints Jim Dillon, CEO of Veterans Affairs Medical Devices, as Chief Executive Officer IG News
- Feb 21, 2023: Raised $15.0M
See plans & pricing → Track BiVACOR ’s funding, hiring, and signals — with verified contacts — on Fundz.